DDD Partners LLC Has $17.99 Million Stake in Johnson & Johnson (NYSE:JNJ)

DDD Partners LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 114,774 shares of the company's stock after buying an additional 13,091 shares during the quarter. Johnson & Johnson accounts for 2.4% of DDD Partners LLC's investment portfolio, making the stock its 17th largest holding. DDD Partners LLC's holdings in Johnson & Johnson were worth $17,990,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Highland Capital Management LLC raised its position in Johnson & Johnson by 0.6% during the 4th quarter. Highland Capital Management LLC now owns 91,851 shares of the company's stock worth $14,397,000 after buying an additional 551 shares during the last quarter. Columbia Trust Co 01012016 increased its holdings in shares of Johnson & Johnson by 10.2% in the 4th quarter. Columbia Trust Co 01012016 now owns 17,954 shares of the company's stock valued at $2,814,000 after purchasing an additional 1,666 shares in the last quarter. Family Legacy Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the 4th quarter. Family Legacy Inc. now owns 31,482 shares of the company's stock valued at $4,934,000 after purchasing an additional 198 shares in the last quarter. PFG Investments LLC increased its holdings in shares of Johnson & Johnson by 1.2% in the 4th quarter. PFG Investments LLC now owns 20,571 shares of the company's stock valued at $3,224,000 after purchasing an additional 238 shares in the last quarter. Finally, Cultivar Capital Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $814,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, March 13th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an "equal weight" rating for the company in a report on Wednesday, January 24th. Wells Fargo & Company downgraded shares of Johnson & Johnson from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 28th. Finally, UBS Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the company from $167.00 to $180.00 in a report on Friday, December 1st. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $177.31.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company's stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company's stock, valued at $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ traded up $0.23 during mid-day trading on Friday, hitting $158.19. The company had a trading volume of 6,181,503 shares, compared to its average volume of 7,203,187. The business's 50-day simple moving average is $158.65 and its 200-day simple moving average is $156.70. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The stock has a market cap of $381.20 billion, a PE ratio of 11.45, a P/E/G ratio of 2.65 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business's quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.35 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were paid a $1.19 dividend. The ex-dividend date was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson's dividend payout ratio (DPR) is presently 34.47%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.